177 related articles for article (PubMed ID: 30610278)
1. Immunoparesis recovery 1 year after ASCT is independently associated with favorable survival in patients with symptomatic multiple myeloma who undergo autologous stem cell transplantation.
Gao W; Li J; Wu Y; Li Y; Leng Y; Liu A; Yang G; Tian Y; Wang H; Wang G; Wu Z; Ren Z; Chen W
Ann Hematol; 2019 May; 98(5):1177-1184. PubMed ID: 30610278
[TBL] [Abstract][Full Text] [Related]
2. Immunoparesis in symptomatic multiple myeloma at diagnosis affects PFS with bortezomib-containing induction therapy, but not ASCT consolidation.
Gao W; Li J; Jian Y; Yang G; Wu Y; Li Y; Len Y; Liu A; Tian Y; Wang H; Zhou H; Zhang Z; Chen W
Int J Hematol; 2019 Feb; 109(2):169-174. PubMed ID: 30311142
[TBL] [Abstract][Full Text] [Related]
3. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
4. Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival.
Dávila J; González-Calle V; Escalante F; Cerdá S; Puig N; García-Sanz R; Bárez A; Montes C; López R; Alonso JM; Aguilar C; García-Mateo A; Labrador J; Aguilera C; García-Coca A; Hernández R; Mateos MV; Ocio EM
Br J Haematol; 2022 Jul; 198(2):278-287. PubMed ID: 35383901
[TBL] [Abstract][Full Text] [Related]
5. Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma.
Chakraborty R; Rybicki L; Nakashima MO; Dean RM; Faiman BM; Samaras CJ; Rosko N; Dysert H; Valent J; Anwer F
Br J Haematol; 2020 Jun; 189(6):1074-1082. PubMed ID: 32108328
[TBL] [Abstract][Full Text] [Related]
6. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
7. Immunoparesis and polyclonal immunoglobulin recovery after auto-SCT for patients with multiple myeloma treated at a single institution.
Jimenez-Zepeda VH; Duggan P; Neri P; Chaudhry A; Tay J; Bahlis N
Leuk Lymphoma; 2018 Aug; 59(8):1920-1926. PubMed ID: 29160734
[TBL] [Abstract][Full Text] [Related]
8. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
9. Severe and continuous immunoparesis during induction or maintenance therapy in nontransplant patients with multiple myeloma is a sign of poor prognosis.
Chen Y; Chen Z; Cao J; Lin L; Li J
Hematology; 2024 Dec; 29(1):2329378. PubMed ID: 38470208
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival and polyclonal immunoglobulin reconstitution after allogeneic stem cell transplantation in multiple myeloma.
Eisfeld C; Eßeling E; Wullenkord R; Khandanpour C; Reusch J; Mikesch JH; Reicherts C; Kerkhoff A; Schliemann C; Kessler T; Mesters RM; Berdel WE; Lenz G; Stelljes M
Ann Hematol; 2020 Aug; 99(8):1907-1915. PubMed ID: 32444892
[TBL] [Abstract][Full Text] [Related]
11. Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma.
González-Calle V; Cerdá S; Labrador J; Sobejano E; González-Mena B; Aguilera C; Ocio EM; Vidriales MB; Puig N; Gutiérrez NC; García-Sanz R; Alonso JM; López R; Aguilar C; de Coca AG; Hernández R; Hernández JM; Escalante F; Mateos MV
Haematologica; 2017 May; 102(5):922-931. PubMed ID: 28126960
[TBL] [Abstract][Full Text] [Related]
12. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
[TBL] [Abstract][Full Text] [Related]
13. [Retrospective analysis on therapeutic effect of autologous hematopoietic stem cell transplantation in multiple myeloma patients].
Wang J; Fu CC; Wu DP; Sun AN; Xue SL; Xin X; Hu XH; Wang Y; Qiu HY; Jin ZM; Miao M; Tang XW; Han Y; Ma X; He GS; Chang WR; Chen SN
Zhonghua Yi Xue Za Zhi; 2013 Jan; 93(2):114-8. PubMed ID: 23648347
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of immunoparesis at diagnosis and after treatment onset in patients with light-chain amyloidosis.
Rodríguez-Lobato LG; Fernández de Larrea C; Cibeira MT; Tovar N; Isola I; Aróstegui JI; Rosiñol L; Díaz T; Lozano E; Yagüe J; Bladé J
Amyloid; 2017 Dec; 24(4):245-252. PubMed ID: 29052436
[TBL] [Abstract][Full Text] [Related]
15. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival.
Jimenez-Zepeda VH; Mikhael J; Winter A; Franke N; Masih-Khan E; Trudel S; Chen C; Kukreti V; Reece DE
Biol Blood Marrow Transplant; 2012 May; 18(5):773-9. PubMed ID: 22062804
[TBL] [Abstract][Full Text] [Related]
16. Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft.
Gössi U; Jeker B; Mansouri Taleghani B; Bacher U; Novak U; Betticher D; Egger T; Zander T; Pabst T
Hematol Oncol; 2018 Apr; 36(2):436-444. PubMed ID: 29363149
[TBL] [Abstract][Full Text] [Related]
17. Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.
Zannetti BA; Tacchetti P; Pantani L; Gamberi B; Tosi P; Rocchi S; Cellini C; Ronconi S; Pezzi A; Mancuso K; Rizzello I; Caratozzolo I; Martello M; Dozza L; Cavo M; Zamagni E
Ann Hematol; 2017 Dec; 96(12):2071-2078. PubMed ID: 29063955
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic significance of immunoparesis in newly diagnosed multiple myeloma patients who achieved deep response].
Yin JH; Xu TT; Wang Y; Chen WM; Liu AJ
Zhonghua Nei Ke Za Zhi; 2022 Oct; 61(10):1152-1157. PubMed ID: 36207970
[No Abstract] [Full Text] [Related]
19. Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma.
Lemieux E; Hulin C; Caillot D; Tardy S; Dorvaux V; Michel J; Gastinne T; Rossi C; Legouge C; Touzeau C; Planche L; Loirat M; Lafon I; Moreau P
Biol Blood Marrow Transplant; 2013 Mar; 19(3):445-9. PubMed ID: 23186983
[TBL] [Abstract][Full Text] [Related]
20. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT).
Björkstrand B; Svensson H; Goldschmidt H; Ljungman P; Apperley J; Mandelli F; Marcus R; Boogaerts M; Alegre A; Remes K; Cornelissen JJ; Bladé J; Lenhoff S; Iriondo A; Carlson K; Volin L; Littlewood T; Goldstone AH; San Miguel J; Schattenberg A; Gahrton G
Bone Marrow Transplant; 2001 Mar; 27(5):511-5. PubMed ID: 11313685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
